Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -46.21% is 11% above its 5-year average of -52.01%, around the middle of its 5-year range (-91.26%–9.85%).
165.42% below its 12-month average of -17.41%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -8.74%.
RETURN ON ASSETS (ROA)
-46.21%
RETURN ON ASSETS (ROA) AVG TTM
-17.41%
RETURN ON ASSETS (ROA) AVG 3Y
-49.70%
RETURN ON ASSETS (ROA) AVG 5Y
-52.01%
RETURN ON ASSETS (ROA) AVG 10Y
-70.52%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-165.42%
CURRENT VS 3Y AVG
+7.02%
CURRENT VS 5Y AVG
+11.15%
CURRENT VS 10Y AVG
+34.48%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-43.33%
vs the sector median at left
Kiora Pharmaceuticals, Inc.
Market Cap
$11.12M
Return on Assets (ROA)
-46.21%
TTM Avg
-17.41%
3Y Avg
-49.70%
5Y Avg
-52.01%
Market Cap
$11.09M
Return on Assets (ROA)
-154.89%
TTM Avg
-40.68%
3Y Avg
-87.98%
5Y Avg
-439.28%
Market Cap
$11.08M
Return on Assets (ROA)
-185.94%
TTM Avg
-166.39%
3Y Avg
-133.67%
5Y Avg
-110.62%
Market Cap
$11.22M
Return on Assets (ROA)
-189.22%
TTM Avg
-102.23%
3Y Avg
-127.28%
5Y Avg
-98.28%
Market Cap
$11.03M
Return on Assets (ROA)
-198.70%
TTM Avg
-189.50%
3Y Avg
-187.22%
5Y Avg
-200.18%
Market Cap
$11.25M
Return on Assets (ROA)
-132.59%
TTM Avg
-75.28%
3Y Avg
-65.73%
5Y Avg
-52.31%
Market Cap
$10.82M
Return on Assets (ROA)
-404.58%
TTM Avg
-269.82%
3Y Avg
-269.82%
5Y Avg
-269.82%
Market Cap
$10.79M
Return on Assets (ROA)
-98.26%
TTM Avg
-77.06%
3Y Avg
-65.68%
5Y Avg
-62.77%
Market Cap
$11.53M
Return on Assets (ROA)
-90.19%
TTM Avg
-82.55%
3Y Avg
-92.57%
5Y Avg
-79.83%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kiora Pharmaceuticals, Inc. (KPRX) | $11.12M | -46.21% | -17.41% | -49.70% | -52.01% |
| BioVie Inc. (BIVI)vs › | $11.09M | -154.89% | -40.68% | -87.98% | -439.28% |
| Cerenome, Inc. (CNSY)vs › | $11.08M | -185.94% | -166.39% | -133.67% | -110.62% |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.22M | -189.22% | -102.23% | -127.28% | -98.28% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.03M | -198.70% | -189.50% | -187.22% | -200.18% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.25M | -132.59% | -75.28% | -65.73% | -52.31% |
| Caring Brands, Inc. (CABR)vs › | $10.82M | -404.58% | -269.82% | -269.82% | -269.82% |
| Pluri Inc. (PLUR)vs › | $10.79M | -98.26% | -77.06% | -65.68% | -62.77% |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.53M | -90.19% | -82.55% | -92.57% | -79.83% |
| Senti Biosciences, Inc. (SNTI)vs › | $10.58M | -149.72% | -86.94% | -66.39% | -60.64% |
ROA
-46.2%
ROE
-65.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -44.67% |
| 2024-12-31 | 9.85% |
| 2023-12-31 | -91.26% |
| 2022-12-31 | -72.72% |
| 2021-12-31 | -68.41% |
| 2020-12-31 | -44.84% |
| 2019-12-31 | -70.18% |
| 2018-12-31 | -75.71% |
| 2017-12-31 | -92.40% |
| 2016-12-31 | -137.13% |
| 2015-12-31 | -88.28% |
| 2014-12-31 | -126.13% |
| 2013-12-31 | -560.46% |
| 2012-12-31 | -257.57% |
